Review



pgl2 e cad 108 ebox mut luc  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Addgene inc pgl2 e cad 108 ebox mut luc
    (A) Luciferase reporter assay of the E-cadherin promoter with an intact (E-cad <t>(−108)-WT-Luc)</t> or mutated (E-cad (−108) <t>Ebox</t> Mut-Luc) Ebox site in cells with or without Atg5 knockout. (B) Immunoblotting in cells with or without Atg5 knockout. (C-D) Immunofluorescence assay of p62/Twist1 (C) or LC3/Twist1 (D) in cells with or without Atg5 knockout treated with or without rapamycin (500 nM) for 6 h. Scale bar, 10 μm. DAPI is used as the nuclear counterstain. (E-F) Immunoblotting in cells with or without Atg5 knockout treated with or without CHX (100 μg/ml, E) or MG132 (10 μM, F) over a time course. (F) Immunoblotting in mouse skin with or without Atg7 knockout. (H) Immunoblotting in cells with or without Atg7 knockout in combination with Atg7 overexpression.
    Pgl2 E Cad 108 Ebox Mut Luc, supplied by Addgene inc, used in various techniques. Bioz Stars score: 90/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pgl2+e+cad+108+ebox+mut+luc/bio_rxiv__2023__10__31__564991-114-5-18?v=Addgene+inc
    Average 90 stars, based on 6 article reviews
    pgl2 e cad 108 ebox mut luc - by Bioz Stars, 2026-07
    90/100 stars

    Images

    1) Product Images from "Autophagy regulates tumor growth and metastasis"

    Article Title: Autophagy regulates tumor growth and metastasis

    Journal: bioRxiv

    doi: 10.1101/2023.10.31.564991

    (A) Luciferase reporter assay of the E-cadherin promoter with an intact (E-cad (−108)-WT-Luc) or mutated (E-cad (−108) Ebox Mut-Luc) Ebox site in cells with or without Atg5 knockout. (B) Immunoblotting in cells with or without Atg5 knockout. (C-D) Immunofluorescence assay of p62/Twist1 (C) or LC3/Twist1 (D) in cells with or without Atg5 knockout treated with or without rapamycin (500 nM) for 6 h. Scale bar, 10 μm. DAPI is used as the nuclear counterstain. (E-F) Immunoblotting in cells with or without Atg5 knockout treated with or without CHX (100 μg/ml, E) or MG132 (10 μM, F) over a time course. (F) Immunoblotting in mouse skin with or without Atg7 knockout. (H) Immunoblotting in cells with or without Atg7 knockout in combination with Atg7 overexpression.
    Figure Legend Snippet: (A) Luciferase reporter assay of the E-cadherin promoter with an intact (E-cad (−108)-WT-Luc) or mutated (E-cad (−108) Ebox Mut-Luc) Ebox site in cells with or without Atg5 knockout. (B) Immunoblotting in cells with or without Atg5 knockout. (C-D) Immunofluorescence assay of p62/Twist1 (C) or LC3/Twist1 (D) in cells with or without Atg5 knockout treated with or without rapamycin (500 nM) for 6 h. Scale bar, 10 μm. DAPI is used as the nuclear counterstain. (E-F) Immunoblotting in cells with or without Atg5 knockout treated with or without CHX (100 μg/ml, E) or MG132 (10 μM, F) over a time course. (F) Immunoblotting in mouse skin with or without Atg7 knockout. (H) Immunoblotting in cells with or without Atg7 knockout in combination with Atg7 overexpression.

    Techniques Used: Luciferase, Reporter Assay, Knock-Out, Western Blot, Immunofluorescence, Over Expression

    (A) Immunoblotting in A431 cells with or without overexpression of p62 and/or Twist1. (B) Luciferase reporter assay of the E-cadherin promoter with an intact (E-cad (−108) WT-Luc) or mutated (E-cad (−108) Mut-Luc) Ebox site in cells as in A. (C) Wound healing assay of cell migration in cells as in A. (D) MTS assay of cells proliferation of cells as in A. (E) Tumor growth from cells as in A. (F) Number of lung tumor nodules per at 14 weeks following injection. (G) Immunoblotting in A375 cells with or without p62 overexpression. (H) Tumor growth from cells as in G. (I) Immunoblotting in A375 cells transfected with or without knockdown of Atg7 or p62. (J) Tumor growth from cells as in I. (K) Immunoblotting in HaCaT cells with or without p62 knockdown and treated with or without EGF/TGF-β)over a time course. (L) qRT-PCR analysis of Twist1 in HaCaT as in K treated with EGF/TGF-β for 48 h. (M) qRT-PCR analysis of p62. Data are shown from three independent experiments (mean±S.D.). n=3. *, P <0.05; compared with WT Con cells (B); #, P <0.05; compared with the WT group (B); *, P <0.05; compared with the Con, A431-p62, and A431-Twist1 groups (E); **, P <0.01; compared with the A431-Twist1 group (F).
    Figure Legend Snippet: (A) Immunoblotting in A431 cells with or without overexpression of p62 and/or Twist1. (B) Luciferase reporter assay of the E-cadherin promoter with an intact (E-cad (−108) WT-Luc) or mutated (E-cad (−108) Mut-Luc) Ebox site in cells as in A. (C) Wound healing assay of cell migration in cells as in A. (D) MTS assay of cells proliferation of cells as in A. (E) Tumor growth from cells as in A. (F) Number of lung tumor nodules per at 14 weeks following injection. (G) Immunoblotting in A375 cells with or without p62 overexpression. (H) Tumor growth from cells as in G. (I) Immunoblotting in A375 cells transfected with or without knockdown of Atg7 or p62. (J) Tumor growth from cells as in I. (K) Immunoblotting in HaCaT cells with or without p62 knockdown and treated with or without EGF/TGF-β)over a time course. (L) qRT-PCR analysis of Twist1 in HaCaT as in K treated with EGF/TGF-β for 48 h. (M) qRT-PCR analysis of p62. Data are shown from three independent experiments (mean±S.D.). n=3. *, P <0.05; compared with WT Con cells (B); #, P <0.05; compared with the WT group (B); *, P <0.05; compared with the Con, A431-p62, and A431-Twist1 groups (E); **, P <0.01; compared with the A431-Twist1 group (F).

    Techniques Used: Western Blot, Over Expression, Luciferase, Reporter Assay, Wound Healing Assay, Migration, MTS Assay, Injection, Transfection, Knockdown, Quantitative RT-PCR



    Similar Products

    pgl2 e cad 108 ebox mut luc  (Addgene inc)
    90
    Addgene inc pgl2 e cad 108 ebox mut luc
    (A) Luciferase reporter assay of the E-cadherin promoter with an intact (E-cad <t>(−108)-WT-Luc)</t> or mutated (E-cad (−108) <t>Ebox</t> Mut-Luc) Ebox site in cells with or without Atg5 knockout. (B) Immunoblotting in cells with or without Atg5 knockout. (C-D) Immunofluorescence assay of p62/Twist1 (C) or LC3/Twist1 (D) in cells with or without Atg5 knockout treated with or without rapamycin (500 nM) for 6 h. Scale bar, 10 μm. DAPI is used as the nuclear counterstain. (E-F) Immunoblotting in cells with or without Atg5 knockout treated with or without CHX (100 μg/ml, E) or MG132 (10 μM, F) over a time course. (F) Immunoblotting in mouse skin with or without Atg7 knockout. (H) Immunoblotting in cells with or without Atg7 knockout in combination with Atg7 overexpression.
    Pgl2 E Cad 108 Ebox Mut Luc, supplied by Addgene inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pgl2+e+cad+108+ebox+mut+luc/bio_rxiv__2023__10__31__564991-114-5-18?v=Addgene+inc
    Average 90 stars, based on 1 article reviews
    pgl2 e cad 108 ebox mut luc - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Luciferase reporter assay of the E-cadherin promoter with an intact (E-cad (−108)-WT-Luc) or mutated (E-cad (−108) Ebox Mut-Luc) Ebox site in cells with or without Atg5 knockout. (B) Immunoblotting in cells with or without Atg5 knockout. (C-D) Immunofluorescence assay of p62/Twist1 (C) or LC3/Twist1 (D) in cells with or without Atg5 knockout treated with or without rapamycin (500 nM) for 6 h. Scale bar, 10 μm. DAPI is used as the nuclear counterstain. (E-F) Immunoblotting in cells with or without Atg5 knockout treated with or without CHX (100 μg/ml, E) or MG132 (10 μM, F) over a time course. (F) Immunoblotting in mouse skin with or without Atg7 knockout. (H) Immunoblotting in cells with or without Atg7 knockout in combination with Atg7 overexpression.

    Journal: bioRxiv

    Article Title: Autophagy regulates tumor growth and metastasis

    doi: 10.1101/2023.10.31.564991

    Figure Lengend Snippet: (A) Luciferase reporter assay of the E-cadherin promoter with an intact (E-cad (−108)-WT-Luc) or mutated (E-cad (−108) Ebox Mut-Luc) Ebox site in cells with or without Atg5 knockout. (B) Immunoblotting in cells with or without Atg5 knockout. (C-D) Immunofluorescence assay of p62/Twist1 (C) or LC3/Twist1 (D) in cells with or without Atg5 knockout treated with or without rapamycin (500 nM) for 6 h. Scale bar, 10 μm. DAPI is used as the nuclear counterstain. (E-F) Immunoblotting in cells with or without Atg5 knockout treated with or without CHX (100 μg/ml, E) or MG132 (10 μM, F) over a time course. (F) Immunoblotting in mouse skin with or without Atg7 knockout. (H) Immunoblotting in cells with or without Atg7 knockout in combination with Atg7 overexpression.

    Article Snippet: PGL2 E-cad (108) WT-Luc and PGL2 E-cad (108) Ebox Mut-Luc were kindly provided by Dr. Eric R. Fearon (Addgene plasmids 19291 and 19290)( ).

    Techniques: Luciferase, Reporter Assay, Knock-Out, Western Blot, Immunofluorescence, Over Expression

    (A) Immunoblotting in A431 cells with or without overexpression of p62 and/or Twist1. (B) Luciferase reporter assay of the E-cadherin promoter with an intact (E-cad (−108) WT-Luc) or mutated (E-cad (−108) Mut-Luc) Ebox site in cells as in A. (C) Wound healing assay of cell migration in cells as in A. (D) MTS assay of cells proliferation of cells as in A. (E) Tumor growth from cells as in A. (F) Number of lung tumor nodules per at 14 weeks following injection. (G) Immunoblotting in A375 cells with or without p62 overexpression. (H) Tumor growth from cells as in G. (I) Immunoblotting in A375 cells transfected with or without knockdown of Atg7 or p62. (J) Tumor growth from cells as in I. (K) Immunoblotting in HaCaT cells with or without p62 knockdown and treated with or without EGF/TGF-β)over a time course. (L) qRT-PCR analysis of Twist1 in HaCaT as in K treated with EGF/TGF-β for 48 h. (M) qRT-PCR analysis of p62. Data are shown from three independent experiments (mean±S.D.). n=3. *, P <0.05; compared with WT Con cells (B); #, P <0.05; compared with the WT group (B); *, P <0.05; compared with the Con, A431-p62, and A431-Twist1 groups (E); **, P <0.01; compared with the A431-Twist1 group (F).

    Journal: bioRxiv

    Article Title: Autophagy regulates tumor growth and metastasis

    doi: 10.1101/2023.10.31.564991

    Figure Lengend Snippet: (A) Immunoblotting in A431 cells with or without overexpression of p62 and/or Twist1. (B) Luciferase reporter assay of the E-cadherin promoter with an intact (E-cad (−108) WT-Luc) or mutated (E-cad (−108) Mut-Luc) Ebox site in cells as in A. (C) Wound healing assay of cell migration in cells as in A. (D) MTS assay of cells proliferation of cells as in A. (E) Tumor growth from cells as in A. (F) Number of lung tumor nodules per at 14 weeks following injection. (G) Immunoblotting in A375 cells with or without p62 overexpression. (H) Tumor growth from cells as in G. (I) Immunoblotting in A375 cells transfected with or without knockdown of Atg7 or p62. (J) Tumor growth from cells as in I. (K) Immunoblotting in HaCaT cells with or without p62 knockdown and treated with or without EGF/TGF-β)over a time course. (L) qRT-PCR analysis of Twist1 in HaCaT as in K treated with EGF/TGF-β for 48 h. (M) qRT-PCR analysis of p62. Data are shown from three independent experiments (mean±S.D.). n=3. *, P <0.05; compared with WT Con cells (B); #, P <0.05; compared with the WT group (B); *, P <0.05; compared with the Con, A431-p62, and A431-Twist1 groups (E); **, P <0.01; compared with the A431-Twist1 group (F).

    Article Snippet: PGL2 E-cad (108) WT-Luc and PGL2 E-cad (108) Ebox Mut-Luc were kindly provided by Dr. Eric R. Fearon (Addgene plasmids 19291 and 19290)( ).

    Techniques: Western Blot, Over Expression, Luciferase, Reporter Assay, Wound Healing Assay, Migration, MTS Assay, Injection, Transfection, Knockdown, Quantitative RT-PCR